Is Moderna, Inc. (MRNA) The Worst Performing S&P 500 Stock In …

Oct 30, 2024 · We recently published a list of the 10 Worst Performing Stocks in S&P 500 in 2024. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) …

$9
OFF

Moderna Is One Of The S&P 500’s Worst Performers. It Looks Too …

2 weeks from now

Shares of Moderna have been hammered by disappointing Covid vaccine sales, the company’s heavy losses—an estimated $9 a share for 2024—and management’s move to push out the …

barrons.com

7%
OFF

Moderna Down Over 7%, Worst Performer In The S&P 500 And

2 weeks from now

Aug 9, 2021 · Moderna, Inc. (MRNA) is currently at $106.53, down $8.06 or 7.03% --On pace for largest percent decrease since April 17, 2023, when it fell 8.36% --Snaps a three day winning …

morningstar.com

2%
OFF

Moderna’s Stock Pummeled To Pace The S&P 500’s ... - MarketWatch

2 weeks from now

The biotechnology and COVID vaccine company’s stock has shed 17.2% during its current losing streak, the worst five-day performance since it plunged 19.2% during the five-day stretch that …

marketwatch.com

21%
OFF

Why Moderna Stock Just Crashed 21% - The Motley Fool

2 weeks from now

2 days ago · Most analysts polled by S&P Global Market Intelligence don't see Moderna turning profitable again until 2029 at the earliest. If today's guidance wasn't enough to scare you away …

fool.com

6%
OFF

Moderna Shares Slump Amid Concerns About COVID-19 Vaccine …

2 weeks from now

Oct 16, 2023 · Moderna was the worst-performing stock in the S&P 500 on Monday as shares lost over 6% after the biotech firm said it “remains comfortable” with its full-year guidance, but …

investopedia.com

21%
OFF

Why Moderna Stock Just Crashed 21% - Yahoo Finance

2 weeks from now

1 day ago · Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET …

yahoo.com

$1
OFF

Moderna's $1 Billion Revenue Forecast Cut Sends Stock

2 weeks from now

1 day ago · Moderna shares tumbled Monday after the company cut its 2025 revenue forecast by $1 billion. The company expects much of its revenue to be realized in the back half of the year …

investopedia.com

50%
OFF

This Biotech Is One Of The S&P 500’s Worst Performers. It Looks

2 weeks from now

Moderna stock, down over 50% this year to $43, is one of the worst performers in the S&P 500. It also looks too cheap. Shares have been hammered by disappointing Covid vaccine sales, the …

msn.com

45%
OFF

Moderna Earnings Beat Estimates. Why The Stock Is Sinking. - MSN

2 weeks from now

Moderna was one of the worst performers in the S&P 500 in 2023, dropping 45% that year as plummeting demand for its Covid vaccine led the company to repeatedly slash its sales …

msn.com

5%
OFF

Moderna, Other Vaccine Stocks Retreat After Bird-flu Gains

2 weeks from now

Moderna is the S&P 500's worst performer Tuesday, as vaccine stocks broadly are giving up some of their recent bird-flu gains. Moderna shares are down 9.5% Tuesday afternoon, on …

marketwatch.com

27%
OFF

Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled …

2 weeks from now

Aug 5, 2024 · Stock Lists Update; Relative Strength at New High; ... On the stock market today, Moderna stock fell 3.3% to 83.75, ... top-performing stock lists, and educational content.

investors.com

96%
OFF

Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

2 weeks from now

Oct 14, 2024 · The most recent trading session ended with Moderna (MRNA) standing at $57.73, reflecting a -0.96% shift from the previouse trading day's closing. This change lagged the S&P …

nasdaq.com

56%
OFF

Moderna (MRNA) Stock Drops Despite Market Gains: Important

2 weeks from now

Oct 8, 2024 · Moderna (MRNA) closed at $58.39 in the latest trading session, marking a -0.56% move from the prior day. The stock's performance was behind the S&P 500's daily gain of …

nasdaq.com

94%
OFF

Moderna Stock Has Lost 94% Of Its Value Over Four Years. Is It A …

2 weeks from now

1 day ago · Related news Moderna Crashes 17%. 'No Inflection In Sight' After Guidance Cut, CMV Shortfall. 1/13/2025 Moderna stock crashed Monday after the firm slashed its outlooks …

investors.com

FAQs about Is Moderna, Inc. (MRNA) The Worst Performing S&P 500 Stock In … Coupon?

Is Moderna a good stock to buy?

Moderna stock, down over 50% this year to $43, is one of the worst performers in the S&P 500. It also looks too cheap. Shares have been hammered by disappointing Covid vaccine sales, the company’s heavy losses—an estimated $9 a share for 2024—and management’s move to push out the year of projected profitability to 2028 from 2026. ...

Is Moderna stock going down?

The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. ...

Is Moderna the S&P 500's worst performer Tuesday?

Moderna is the S&P 500's worst performer Tuesday, as vaccine stocks broadly are giving up some of their recent bird-flu gains. Moderna shares are down 9.5% Tuesday afternoon, on pace for their biggest percentage decline since late 2022. ...

Will Moderna get a takeover interest from Merck?

Moderna might also generate takeover interest, perhaps from oncology partner Merck. Wall Street analysts generally are lukewarm on Moderna, but HSBC analyst Yifeng Liu recently upgraded the stock to Buy from Hold, citing a “pipeline that deserves more attention than it gets credit for.” He has a $58 price target on the stock. ...

Will Moderna lose money in 4 years?

Analysts think Moderna will lose money for at least four years. Moderna 's (MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated investors on its 2024 performance and released new guidance for 2025. ...

Does Moderna have more competitive pressure than last year?

“I think there’s just more competitive pressure because of the market share we gained last year,” Bancel said. “For those two products, there’s much more competitive pressure than there was last year.” Moderna now expects net product sales of between $3 billion and $3.5 billion in 2024, down from its prior estimate of $4 billion. ...